Categories: Health

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.

The RSU awards and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.

The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.



GlobeNews Wire

Recent Posts

Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics

The Atlas will expand known evolutionary genetic diversity by 100x, collecting novel genomic data from…

54 minutes ago

Manipal Hospital Varthur Road Celebrates World Kidney Day 2026 by Honouring ‘Kidney Champions’

BENGALURU, India, March 18, 2026 /PRNewswire/ -- Manipal Hospital, Varthur Road marked World Kidney Day…

54 minutes ago

Innodisk at NVIDIA GTC 2026: Accelerating Real-World AI for Healthcare and Mobility with Full-Stack Edge Solutions

SAN JOSE, Calif., March 18, 2026 /PRNewswire/ -- Innodisk, a leading global AI solution provider,…

54 minutes ago

Vieworks to Debut VISQUE DPS LH210 at USCAP 2026, a Single Scanner for Both Cytology and Histology

High-throughput, mid capacity LH210 expands the VISQUE DPS lineup with fast scanning, optimized data size, and…

54 minutes ago

Metabolon Collaborates with The Michael J. Fox Foundation to Advance Multiomic Analyses for Parkinson’s Research

Partnership supports expanded biomarker discovery efforts within MJFF's Parkinson's Progression Markers InitiativeMORRISVILLE, N.C., March 17,…

54 minutes ago

Dreame Technology expands its product portfolio with the launch of L40 Ultra AE and D20 Ultra All-in-one robotic vacuums in India

Starting 18th March, L40 Ultra AE and D20 Ultra will be available on Amazon India…

2 hours ago